Analysts Expect Design Therapeutics, Inc. (NASDAQ:DSGN) Will Post Earnings of -$0.22 Per Share

Analysts predict that Design Therapeutics, Inc. (NASDAQ:DSGN) will announce earnings of ($0.22) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Design Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.22). The business is scheduled to announce its next earnings results on Tuesday, February 8th.

According to Zacks, analysts expect that Design Therapeutics will report full year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.86) to ($0.80). For the next financial year, analysts expect that the business will report earnings of ($1.04) per share, with EPS estimates ranging from ($1.31) to ($0.76). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Design Therapeutics.

Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Tuesday, November 9th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07).

Separately, Zacks Investment Research cut Design Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 11th.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. EcoR1 Capital LLC lifted its stake in Design Therapeutics by 47.9% during the third quarter. EcoR1 Capital LLC now owns 1,863,098 shares of the company’s stock worth $27,369,000 after purchasing an additional 603,079 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Design Therapeutics by 8.9% during the third quarter. Bank of New York Mellon Corp now owns 36,476 shares of the company’s stock worth $536,000 after purchasing an additional 2,979 shares during the last quarter. Wellington Management Group LLP lifted its stake in Design Therapeutics by 1.7% during the third quarter. Wellington Management Group LLP now owns 955,588 shares of the company’s stock worth $14,037,000 after purchasing an additional 16,226 shares during the last quarter. Millennium Management LLC bought a new position in Design Therapeutics during the third quarter worth $208,000. Finally, Rock Springs Capital Management LP increased its position in Design Therapeutics by 0.6% in the third quarter. Rock Springs Capital Management LP now owns 334,050 shares of the company’s stock worth $4,907,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 50.45% of the company’s stock.

Shares of Design Therapeutics stock traded up $0.74 on Friday, hitting $15.85. 81,911 shares of the company’s stock traded hands, compared to its average volume of 80,351. The firm’s 50-day moving average is $18.44 and its 200 day moving average is $17.12. Design Therapeutics has a 52-week low of $12.52 and a 52-week high of $50.50.

Design Therapeutics Company Profile

Design Therapeutics, Inc develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy.

Recommended Story: dividend yield calculator

Get a free copy of the Zacks research report on Design Therapeutics (DSGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.